← Back to patent-cliff list
M-7583
Tier C — Watch / tradeM-7583
Merck & Co Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：BTK
Indications (approved)：B-cell lymphoma, Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma, Mantle cell lymphoma
Regional status
US
Phase II
2016-08-26
EU
Phase II
2016-08-26
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of M-7583?
Approved indications include: B-cell lymphoma, Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma, Mantle cell lymphoma.
When does the M-7583 patent expire?
No public expiry year is available for M-7583 yet; this page updates once verified.
How do I get a quote for M-7583 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-10